An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
复制标题
DOI：
10.1038/sj.bjc.6601267
复制
发表时间：
2003-09-15
影响因子：
8.8
通讯作者：
Abken H
中科院分区：
文献类型：
--
作者：
Heuser C;Ganser M;Hombach A;Brand H;Denton G;Hanisch FG;Abken H
MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases. In MUC1-positive tumours, MHC class I expession is frequently downregulated and MUC1-specific cytotoxic T cells (CTLs) are either not available or in a state of anergy allowing tumour growth without limitation by CTL control. To activate lymphocytes and natural killer (NK) cells, we here generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding, the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells. The fusion protein binds to MUC1-derived peptides and to MUC1-positive tumour cells with the same specificity as does the C595 monoclonal antibody. Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes in vitro. Upon binding to MUC1-positive MCF7 breast carcinoma cells, moreover, the fusion protein activates resting NK cells to tumour cell lysis. These properties make the C595scFv-Fc-IL2 fusion protein a suitable candidate for the immunotherapy of MUC1-positive tumours.
登录
查看更多内容
影响因子：
8.4
作者：
BERRUTI, A;TAMPELLINI, M;DOGLIOTTI, L
通讯作者：
DOGLIOTTI, L
影响因子：
8.8
作者：
Denton, G;Sekowski, M;Price, MR
通讯作者：
Price, MR
影响因子：
4.8
作者：
Engelmann, K;Baldus, SE;Hanisch, FG
通讯作者：
Hanisch, FG
影响因子：
5.8
作者：
Acres, B;Apostolopoulos, V;McKenzie, IFC
通讯作者：
McKenzie, IFC
影响因子：
6.4
作者：
Hamanaka, Y;Suehiro, Y;Hinoda, Y
通讯作者：
Hinoda, Y